



EUROPEAN COMMISSION
HEALTH AND FOOD SAFETY DIRECTORATE-GENERAL

Health systems and products
Medicinal products – authorisations, European Medicines Agency

STAMP 2/008

AGENDA

**2nd Meeting of the Commission Expert Group on
Safe and Timely Access to Medicines for Patients (STAMP)
6 May 2015 (10:00 – 18:00)
Centre A. Borschette, Room AB-3B, Rue Froissart 36,
1040 Brussels, Belgium**

- 1. Opening and adoption of the Agenda**
- 2. Endorsement of the minutes of the 1st STAMP meeting**
- 3. Regulatory tools for early access:**
 - a. Conditional marketing authorisations (CMA)**
 - b. Accelerated assessment**
 - c. Update on EMA's pilot project on Adaptive Pathways**
- 4. Update on other EU initiatives relevant for timely patient access to innovative medicines**
 - a. "EU cooperation on HTA – latest developments" - Tapani Piha, Head of SANTE Unit D3-e-Health and Health Technology Assessment; Prof. Finn Børlum Kristensen, Chair, Executive Committee of EUnetHTA**
 - b. Information about Network of Competent Authorities on Pricing and Reimbursement of Pharmaceutical Products (CAPR)- DG GROW Unit I.3**
- 5. Exchange of experiences from national routes (other than clinical trials) for making available medicines to patients before authorisation: early access schemes, compassionate use etc.**
 - **The UK Early Access to Medicines Scheme - Presentation by the Medicines and Healthcare products Regulatory Agency (MHRA)**
- 6. Introduction of Ministry of Health Labour and Welfare of Japan(MHLW)/Pharmaceuticals and Medical Devices Agency (PMDA) and recent updates in Japan - Mr. Yoshi Sano, PMDA's International Liaison Officer at EMA**

* * *